2018 Annual Meeting | C107 - What Do I Do Now?: Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders

Date Tuesday 04/24/18

Time 01:00 PM - 03:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Daniel Kaufer, MD, FAAN

Topic(s)

Learning Objectives Participants should be able to efficiently identify and assess common neuropsychiatric symptoms; develop a systematic approach to formulating a flexible, comprehensive treatment plan; select appropriate pharmacological therapies for specific target symptoms to ensure safety, improve quality of life, and minimize patient and caregiver distress; better understand possible iatrogenicity and minimize risks associated with polypharmacy; and become familiar with behavioral modification techniques and use community resources for caregiver education and support.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
01:00 PM - 01:20 PM	Speaker	Neuropsychiatric Assessment Daniel Kaufer, MD, FAAN
01:20 PM - 01:40 PM	Speaker	Neuropsychiatric Symptom Management Douglas W. Scharre, MD, FAAN
01:40 PM - 02:50 PM	Speaker	Case Presentations with ARS Daniel Kaufer, MD, FAAN, Douglas W. Scharre, MD, FAAN
02:50 PM - 03:00 PM	Speaker	Wrap-Up / Discussion

Faculty Disclosures
Daniel Kaufer, MD, FAAN	No disclosure on file
Tiffany W. Chow, MD, FAAN	Dr. Chow has received personal compensation for serving as an employee of Alector, Inc.. Dr. Chow has stock in Alector, Inc.. Dr. Chow has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant on grant U19AG079774 with NIA.
Douglas W. Scharre, MD, FAAN	Dr. Scharre has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BrainTest, Inc. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuka. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Scharre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Scharre has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. The institution of Dr. Scharre has received research support from InSightec. The institution of Dr. Scharre has received research support from Alzheimer's Therapeutic Research Institute (ATRI). The institution of Dr. Scharre has received research support from Eisai. The institution of Dr. Scharre has received research support from vTv Therapeutics. The institution of Dr. Scharre has received research support from National Institute of Health. The institution of Dr. Scharre has received research support from Eli Lilly. The institution of Dr. Scharre has received research support from Biogen. The institution of Dr. Scharre has received research support from Roche. The institution of Dr. Scharre has received research support from Percision Medicine. The institution of Dr. Scharre has received research support from Premier Research Group. The institution of Dr. Scharre has received research support from Genetch. The institution of Dr. Scharre has received research support from Avanir. The institution of Dr. Scharre has received research support from Cerevel Therapeutics. The institution of Dr. Scharre has received research support from Janssen. The institution of Dr. Scharre has received research support from Cassava. The institution of Dr. Scharre has received research support from UniQure. The institution of Dr. Scharre has received research support from Cognition Therapeutics. The institution of Dr. Scharre has received research support from Cognitive Research Corporation. The institution of Dr. Scharre has received research support from EIP. The institution of Dr. Scharre has received research support from Cognito. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care. Dr. Scharre has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��